CSF1R and neoplasm: By inhibiting CSF1R, vimseltinib disrupts the tumor microenvironment and induces regression of macrophage-driven tumors.87 The pharmacokinetic (PK) profile supports oral administration, though detailed PK parameters are not yet widely published.